Midazolam sedation in endoscopy

Intranazal midazolam efficacy in upper endoscopy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201110087740N1

Enrollment

105

Registered

2013-04-22

Start date

2010-10-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper endoscopy. Upper endoscopy for evaluation of upper GI diseases

Interventions

Intranazal midazolam 1mg in intervention group and pure water in control..

Treatment - Drugs

Intranazal midazolam 1mg in intervention group and pure water in control.

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: patients aged between 20 to 60 years old candidate for upper endoscopy. Exclusion criteria:GIB; COPD; CHF and intolerance to upper endoscopy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Midazolam sedation for making upper endoscopy more comfort. Timepoint: 2 hours after intervention. Method of measurement: Questionnaire.	—

Secondary

Measure	Time frame
Amnesia after endoscopy. Timepoint: 2 hours after endoscoy. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHajiani Eskandar

Ahvaz University of Medical Sciences and Health Services

eskandarhajiani@yahoo.com+98 611222292

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026